Strong brands for current trends – cannabidiol
13. August 2020
Intensive research on cannabis-based medicines began 20 years ago, and in Germany a cannabis extract was approved under pharmaceutical law for the first time in 2011.
More information can be found in the linked specialist article, which deals with the collected performance data and the unique characteristics of MIGLYOL® 812 N in comparison with other typical carrier oils in CBD tinctures. If you have any further questions, please contact Robert Radsziwil at pharma@ioioleo.de.
Robert Radsziwill
Robert is the Business Development Manager for Functional Excipients in the Pharma Division of IOI Oleo GmbH. Prior to this role he held technical and commercial roles focusing raw materials used in the pharmaceutical and medical device industry for 13 years. In each position he leveraged his diploma degree in Business Chemistry earned at Westfälische Wilhelms-University to drive interdisciplinary projects and work as interface between commercial and technical decision makers. Understanding technical, commercial and regulatory drivers from ideation to successful project-completion is key for him. In his free time he enjoys guitar heavy music as well as cooking for and with family and friends.